---
layout: post
title: "Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products; Draft Guidance for Industry; Extension of the Comment Period"
date: 2026-02-05 18:56:35 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-18235
original_published: 2023-08-24 00:00:00 +0000
significance: 8.00
---

# Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products; Draft Guidance for Industry; Extension of the Comment Period

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** August 24, 2023 00:00 UTC
**Document Number:** 2023-18235

## Summary

The Food and Drug Administration (FDA or we) is extending the comment period for the notice announcing the availability of a draft guidance entitled "Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products; Draft Guidance for Industry," that appeared in the Federal Register of July 14, 2023. We are taking this action in response to requests for an extension to allow interested persons additional time to submit comments.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/08/24/2023-18235/manufacturing-changes-and-comparability-for-human-cellular-and-gene-therapy-products-draft-guidance)
- API: https://www.federalregister.gov/api/v1/documents/2023-18235

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
